FY2024 Earnings Forecast for TRDA Issued By William Blair

Entrada Therapeutics, Inc. (NASDAQ:TRDA) – Research analysts at William Blair raised their FY2024 EPS estimates for Entrada Therapeutics in a report released on Tuesday, November 5th. William Blair analyst M. Minter now expects that the company will post earnings per share of $1.19 for the year, up from their previous forecast of $0.43. The consensus estimate for Entrada Therapeutics’ current full-year earnings is $0.68 per share. William Blair also issued estimates for Entrada Therapeutics’ Q4 2024 earnings at ($0.69) EPS, Q1 2025 earnings at ($0.72) EPS, Q2 2025 earnings at ($0.75) EPS, Q3 2025 earnings at ($0.79) EPS, Q4 2025 earnings at ($0.69) EPS and FY2025 earnings at ($2.95) EPS.

Entrada Therapeutics (NASDAQ:TRDA) last released its quarterly earnings data on Tuesday, August 13th. The company reported $1.55 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.90. The business had revenue of $94.69 million for the quarter, compared to the consensus estimate of $55.00 million. Entrada Therapeutics had a return on equity of 35.16% and a net margin of 43.63%.

Other research analysts have also issued research reports about the company. HC Wainwright boosted their target price on Entrada Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday. Oppenheimer increased their target price on Entrada Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a research note on Wednesday.

Entrada Therapeutics Stock Up 0.2 %

NASDAQ:TRDA opened at $18.66 on Thursday. Entrada Therapeutics has a 52-week low of $10.75 and a 52-week high of $19.78. The stock’s 50 day moving average price is $16.33 and its 200 day moving average price is $15.61. The company has a market capitalization of $694.15 million, a PE ratio of 6.30 and a beta of -0.26.

Insider Buying and Selling at Entrada Therapeutics

In other Entrada Therapeutics news, insider Natarajan Sethuraman sold 2,642 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $15.09, for a total transaction of $39,867.78. Following the completion of the transaction, the insider now directly owns 183,816 shares in the company, valued at approximately $2,773,783.44. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, insider Natarajan Sethuraman sold 2,642 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $15.09, for a total value of $39,867.78. Following the completion of the transaction, the insider now owns 183,816 shares of the company’s stock, valued at $2,773,783.44. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Kory James Wentworth sold 3,195 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $14.97, for a total value of $47,829.15. Following the transaction, the chief financial officer now directly owns 76,486 shares in the company, valued at approximately $1,144,995.42. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 10,187 shares of company stock valued at $155,947. Insiders own 7.59% of the company’s stock.

Institutional Trading of Entrada Therapeutics

A number of institutional investors have recently modified their holdings of TRDA. The Manufacturers Life Insurance Company grew its position in Entrada Therapeutics by 3.9% in the second quarter. The Manufacturers Life Insurance Company now owns 57,098 shares of the company’s stock valued at $814,000 after acquiring an additional 2,146 shares in the last quarter. US Bancorp DE bought a new stake in Entrada Therapeutics during the third quarter valued at $42,000. Acadian Asset Management LLC acquired a new stake in shares of Entrada Therapeutics during the first quarter worth $79,000. Rhumbline Advisers boosted its stake in Entrada Therapeutics by 25.3% in the second quarter. Rhumbline Advisers now owns 36,940 shares of the company’s stock valued at $526,000 after acquiring an additional 7,452 shares during the period. Finally, SG Americas Securities LLC bought a new position in shares of Entrada Therapeutics during the third quarter valued at approximately $156,000. Hedge funds and other institutional investors own 86.39% of the company’s stock.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.